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A B S T R A C T
Current study evaluated the processability and characteristics of prills made of an active pharmaceutical in-
gredient/fatty acid (API/FA) suspension instead of previously studied API/FA solutions to enlarge the applica-
tion field of prilling. Metformin hydrochloride (MET) and paracetamol (PAR) were used as model APIs while
both the effect of drug load (10–40%) and FA chain length (C14–C22) were evaluated. API/FA suspensions were
processable on lab-scale prilling equipment without thermal degradation, nozzle obstruction or sedimentation in
function of processing time. The collected prills were spherical (AR≥0.898) with a smooth surface (spheri-
city≥ 0.914) and a particle size of± 2.3mm and 2.4mm for MET and PAR prills, respectively, independent of
drug load and/or FA chain length. In vitro drug release evaluation revealed a faster drug release at higher drug
load, higher API water solubility and shorter FA chain length. Solid state characterisation via XRD and Raman
spectroscopy showed that API and FA crystallinity was maintained after thermal processing via prilling and
during storage. Evaluation of the similarity factor indicated a stable drug release (f2 > 50) from MET and PAR
prills after 6months storage at 25 °C or 40 °C.
1. Introduction
Due to their biocompatibility, low toxicity, low cost and pharma-
ceutical approved status, lipids (e.g. oils, waxes, triglycerides, partial
glycerides, fatty alcohols and fatty acids (FAs)) have gained interest in
the pharmaceutical industry as versatile excipients to mask taste, pro-
tect unstable active pharmaceutical ingredients (APIs), increase the
bioavailability and sustain the dissolution rate (Pivette et al., 2012;
Rosiaux et al., 2014; Jannin et al., 2008; Reitz and Kleinebudde, 2007;
Becker et al., 2015; Aleksovski et al., 2016). Solid lipid-based drug
formulations can be produced via solvent-free melting techniques, such
as melt extrusion, melt coating and spray congealing, all relatively
short, cost-effective and environmentally friendly production processes
(Jannin et al., 2008; Becker et al., 2015; Aleksovski et al., 2016;
Vervaeck et al., 2015). Via spray congealing spherical microspheres
consisting of a drug imbedded in a lipid matrix can be produced
(Passerini et al., 2010; Martins et al., 2013). A specific type of spray
congealing, called prilling, yields larger spherical particles (dia-
meter > 500 µm) resulting in a slower controlled release system and
excellent flow properties for volumetric capsule filling (Rosiaux et al.,
2014; Becker et al., 2015; Séquier et al., 2014; Vervaeck et al., 2013).
Although prilling is widely applied in the agricultural industry for
the production of urea beads (Mehrez et al., 2014; Rahamnian and
Homayoonfard, 2012; Rahmanian et al., 2013; Rahmanian et al., 2015),
its applications in the pharmaceutical field are limited as stated by
Aleksovski et al. (2016). Pivette et al. examined the controlled-release
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mechanism of a highly water-soluble API from lipid microspheres
composed of Compritol 888 and paraffin wax (Pivette et al., 2012).
Vervaeck et al. demonstrated that long chain FAs, such as stearic acid
(SA) and behenic acid (BA), are excellent matrix formers in a multi-
particulate controlled release dosage form manufactured by prilling
(Vervaeck et al., 2013). FAs are used as a versatile pharmaceutical
excipient (e.g. binder during melt granulation (Maejima et al., 1997;
Bhagwat et al., 2008), taste masking (Qi et al., 2006; Robson et al.,
1999), (enteric) hot-melt coating (Patil et al., 2012; Kulah and Kaya,
2011; Jannin and Cuppok, 2013) or matrix for sustained drug release
via melt agglomeration (Bhagwat et al., 2008; Voinovich et al., 2000).
As the API can be dissolved or suspended in a (mixture of) molten
FA during processing, the physical state of the drug during prilling
could affect processing as well as the characteristics of the prills. As
Vervaeck et al. focused on API/FA solutions (e.g. metoprolol tartrate
(MPT) in BA) (Vervaeck et al., 2015), no information is available on the
feasibility of prilling API/FA suspensions, as indicated by Séquier et al.
(Séquier et al., 2014). Therefore, the aim of current study was to
evaluate the potential of prilling for APIs suspended in molten FA. To
fully understand the effect of suspended API particles in the molten FA
during processing, the API-FA solutions of Vervaeck et al. (i.e. MPT in
BA) were further investigated in this study (Vervaeck et al., 2015;
Vervaeck et al., 2013).
In the first part of this study, the processability of API/FA suspen-
sions via prilling was evaluated. An API/FA suspension was defined as
processable when prills could be generated without thermal degrada-
tion, nozzle obstruction or sedimentation during processing at a suffi-
ciently high drug load. The second part of this study characterised the
final prills in terms of size, shape, solid state and dissolution profile.
Droplet formation at the nozzle and its solidification in liquid nitrogen
was visualized via high-speed imaging and quantified via rapid heat-
cool differential scanning calorimetry (RHC). Metformin hydrochloride
(MET) and paracetamol (PAR) were selected as model APIs, both highly
soluble in water and insoluble in FA. Formulations with varying drug
load (10–40%) and FA chain lengths (C14–C22) were produced to
evaluate the processability of API/FA suspensions and their prill char-
acteristics.
2. Materials and methods
2.1. Materials
Four long chain saturated FAs with different carbon chain lengths
(C14, C16, C18 and C22) were evaluated: myristic acid (MA) with a C14
purity of 99.2%, palmitic acid (PA) with a C16 purity of 99.3%, SA with
a C18 purity of 98.3% (Mosselman, Ghlin, Belgium) and BA with a C22
purity of 88.9% (Radiacid 0560, Oleon, Ertvelde, Belgium). The melting
point of MA, PA, SA and BA is 53 °C, 62 °C, 68 °C and 75 °C, respec-
tively. These FAs were combined with MET (Granules, Hyderabad,
India), PAR (Mallinckrodt, Manchester, UK) or MPT (Esteve Quimica,
Barcelona, Spain) as model drugs with a water solubility of 297 g/l, 8 g/
l and 682 g/l (20 °C), respectively. Prills were dissolved in absolute
(> 99.8%) ethanol (VWR, Radnor, United States). Dissolution media
were made with sodium lauryl sulfate (SLS) (Fagron, Waregem,
Belgium), potassium dihydrogen phosphate (VWR, Radnor, United
States), sodium hydroxide (Sigma Aldrich, Saint Louis, United States)
and hydrochloric acid (VWR, Radnor, United States).
2.2. Methods
2.2.1. Prilling
Prills were manufactured using a modified Prilldrop® device (Peira,
Turnhout, Belgium), depicted in Fig. 1. FAs were heated to 30 °C above
their melting temperature and subsequently the API was added to the
molten FA under continuous stirring (350 rpm – 8 cm long stirring bar).
After 15min of intensive stirring at a constant temperature, the prilling
process was started by applying an initial pressure (1 bar) on the re-
servoir to feed the viscous API/FA suspension to the thermostated
nozzle (Tnozzle= Tmelt FA+30 °C; inner nozzle diameter: 445 µm). The
flow rate through this nozzle was controlled with a pneumatic valve
system with a calibrated drop time for non-viscous pure water. In-
dividual API/FA droplets were formed at the nozzle by lowering the
pressure on the vessel (0.1 bar) and adjusting the valve opening (drop
time: 0.03 s; interval: 0.10 s). Under these conditions, approximately
150 API/FA suspension droplets/min were formed at the nozzle. The
individual droplets were quench cooled in liquid nitrogen whereby a
solid matrix system (prill) was formed.
The effect of drug load (10–40%) and FA chain length (C14–C22) on
the processability of API/FA suspensions and the characteristics of prills
was evaluated, manufacturing 12 different formulations (Table 1). All
formulations were produced in duplicate to evaluate the drug content,
solid state, as well as size and shape of the prills for two independent
batches, while the dissolution profile after manufacturing and during
storage was evaluated for one batch.
2.2.2. Thermogravimetric analysis (TGA)
The thermal stability of pure FAs and APIs under extreme processing
conditions (i.e. 2 h at 105 °C) was screened via TGA (Hi-res TGA 2950,
TA instruments, Leatherhead, UK). The samples (± 15mg) were he-
ated to 110 °C and kept isothermal for 2 h while recording the weight
loss.
2.2.3. Hot stage microscopy
The solubility of MET and PAR in molten FAs was determined via
hot stage microscopy (Leica, Wetzlar, Germany). Therefore, a physical
mixture of 1% API in FA was filled in a quartz crucible (diameter:
15mm) and heated to 30 °C above the melting temperature of the FA.
Physical mixtures were obtained after sieving (180 µm) all compounds
followed by homogenous blending (Turbula mixer type T2F, W.A.
Bachofen Maschinenfabrik, Basel, Switzerland). The API was defined as
insoluble in the molten FA when API crystals were still visible (mag-
nification: 100×) after maintaining the physical mixture at the max-
imum processing temperature (Tmelt FA+30 °C) for 1 h.
2.2.4. Rapid heat-cool differential scanning calorimetry (RHC)
To evaluate the crystallization kinetics of API/FA solutions and
suspensions, a prototype RHC (TA Instruments, Leatherhead, UK)
equipped with a liquid nitrogen cooling unit was used. Tzero calibra-
tion was performed at 250 °C/min with sapphire disks, while an indium
standard was used for the temperature and enthalpy calibration.
220 ± 20 µg of pure FA or physical mixtures (125 µm) were filled in
low mass (≤2.1mg) aluminium RHC crucibles. To obtain a pre-treat-
ment similar to the prilling process, all samples were kept 30 °C above
the melting temperature of the used FA for 10min to ensure complete
melting of FA and to allow sufficient time for MPT crystals to dissolve.
Subsequently, the sample was rapidly cooled (250 °C/min) to a specific
crystallization temperature (68.0 °C, 69.0 °C, 70.0 °C, 70.5 °C, 71.0 °C,
71.5 °C and 72.0 °C) and kept isothermal for 2min. Thereafter the
sample was cooled down (500 °C/min) to −50 °C and a new pre-
treatment was started. The time needed to reach the FA crystallization
peak maximum when the crystallization temperature was reached, was
used to compare the crystallization rate of the samples.
2.2.5. Size and shape of the suspended APIs
Since API particles and/or agglomerates can obstruct the nozzle,
particle size and shape distribution of the suspended APIs was de-
termined. The particle size and shape of the dry API powder was ana-
lysed via a dynamic image analyser (Camsizer XT, Retsch Technology,
Haan, Germany) equipped with an air pressure dispersion unit set at
180 – 185 kPa (X-jet, Retsch Technology, Haan, Germany). Powders
were analysed in triplicate to calculate the mean Feret diameter and
weighted average aspect ratio (ratio of the minimal to the maximal
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Feret diameter) based on a volume distribution. Additionally, the shape
of the dry API particles was visualized by scanning electron microscopy
(SEM) (Quanta 200F, Thermo Fisher Scientific, Waltham, USA) after
sputtering with a gold coating (thickness: 45–50 nm) using an Emtech
SC7620 sputter coater (Quorum Technologies, Laughton, United
Kingdom) to improve the electron conductivity of the samples.
To evaluate API agglomeration in a hydrophobic environment such
as molten FAs, laser diffraction (Malvern Mastersizer S long bench,
Malvern Instruments, Malvern, UK) was applied on dispersions of the
API in Miglyol 812® (IOI Oleo, Hamburg, Germany). As a pre-treat-
ment, dispersions were vortexed and subsequently sonicated for 10min
(i.e. standard method), ultrasonically vibrated (4 h – 40 kHz) or high
shear mixed (10min – 6000 rpm) in a Silverson L4R (East
Longmeadow, United States). After transfer to the wet sample disper-
sion unit (1500 rpm) to obtain an obscuration of 10–30%, the samples
were analysed using a 300RF lens (Malvern Instruments, Malvern, UK).
d50 and d90 were determined on a volume-based distribution after
performing measurements in triplicate.
2.2.6. Drug content
Homogeneity of drug content in the prills as a function of processing
time was assessed over a 1 h period at 6min intervals. Drug content was
spectrophotometrically determined using a double beam spectro-
photometer (UV-1650PC, Shimadzu, Antwerp, Belgium) after dissol-
ving ± 35mg prills (i.e. 5 prills) in absolute ethanol. MET concentra-
tions were calculated based on a calibration curve ranging from 1.9 to
9.6 µg/ml at a wavelength of 239 nm. PAR concentrations were calcu-
lated based on a calibration curve ranging from 2.2 to 13.0 µg/ml at a
Fig. 1. Design of the modified Prilldrop device. (a) melt reservoir, (b) reservoir heater and magnetic stirrer, (c) temperature sensor with feedback loop, (d) con-
nection tube between reservoir and nozzle, (e) thermostated nozzle, (f) original nozzle heater, (g) extra nozzle heater, (h) valve, (i) needle (internal diameter:
445 µm) (j) schematic overview of the final seamless nozzle.
Table 1
Overview of API/FA suspensions and the processing temperature used to
evaluate the influence of drug load and type of FA on the processability.
Average drug content of the two formulated batches and maximum relative
drug content deviation of prills as a function of processing time at 6min in-
tervals over a 1 h period are displayed.
Processing temperature and drug content
Formulation Processing temp Average ± SD Max relative deviation
Tmelt FA+ 30 °C (%) (%)
10% MET in BA 105 10.09 ± 0.18 3.60
20% MET in BA 105 19.09 ± 1.05 −12.91
30% MET in MA 83 29.78 ± 0.59 − 4.81
30% MET in PA 92 30.14 ± 0.70 7.25
30% MET in SA 98 29.94 ± 0.58 4.21
30% MET in BA 105 29.28 ± 0.66 − 9.02
40% MET in BA 105 40.36 ± 0.80 3.76
10% PAR in BA 105 10.60 ± 0.33 12.69
20% PAR in MA 83 20.29 ± 0.52 5.45
20% PAR in PA 92 20.81 ± 0.41 7.72
20% PAR in SA 98 21.31 ± 0.54 11.92
20% PAR in BA 105 21.26 ± 0.99 12.59
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wavelength of 250 nm. The deviation in drug content relative to the
targeted drug content for each time interval and the average drug
content of the two independent batches of each formulation were cal-
culated.
Via Raman microscopic mapping (Raman Rxn1 Microprobe, Kaiser
Optical Systems, Ann Arbor, USA) the API distribution in the FA matrix
was evaluated. Cross sections of prills were scanned in both the x and y
directions with a 10× objective lens in area mapping mode using an
exposure time of 5 s with 3 accumulations and a step size of 50 µm. Data
collection and data transfer were automated using HoloGRAMS™ data
collection software (version 2.3.5, Kaiser Optical Systems, Ann Arbor,
USA), the HoloMAP™ data analysis software (version 2.3.5, Kaiser
Optical Systems, Ann Arbor, USA) and Matlab software (version 7.1,
The MathWorks, Natick, MA, USA). Each mapping was evaluated via
multivariate curve resolution (MCR) to evaluate the homogeneity of the
API distribution in the FA matrix. Therefore, all spectra of each map-
ping were merged in a data matrix and baseline corrected via Pearson’s
method and subsequently normalized.
2.2.7. High-speed imaging
Droplet formation at the nozzle and their solidification in liquid
nitrogen was visualized using a Photron Mini AX200 high-speed camera
(San Diego, USA) available at DyMaLab at Ghent University, together
with adequate lighting. The camera was equipped with a fixed focus
macro lens (Tamron, New York, USA), having a 90mm focal length.
Image resolution and frame rate were adjusted during the different
experiments in order to optimize the visualization of droplet formation
and solidification events. The ranges of the image resolutions used were
1024×725 to 640× 464 pixels, and the ranges of the frame rates were
4000–6400 fps.
2.2.8. Size and shape of the prills
Surface and cross section of prills were examined by SEM (Quanta
200F, Thermo Fisher Scientific, Waltham, USA) after sputtering with a
gold coating using an Emtech SC7620 sputter coater (Quorum
Technologies, Laughton, United Kingdom) to improve the electron
conductivity of the samples.
Size and shape (i.e. aspect ratio and sphericity) of the prills were
evaluated via a dynamic imaging analysis technique (QICPIC,
Sympatec, Clausthal-Zellerfeld, Germany). All batches were analysed in
triplicate (± 2 g) and Windox 5 software (Sympatec, Clausthal-
Zellerfeld, Germany) was used to calculate the mean Feret diameter,
weighted average aspect ratio and sphericity (ratio of the perimeter of
the equivalent circle, PEQPC, to the real perimeter) based on a volume
distribution. The average values of the two batches per formulation
were reported.
2.2.9. Rheology of molten mixtures
The viscosity of pure FA, API/FA suspensions and API/FA solutions
was measured using a stress controlled Haake™ Mars III rheometer
(Thermo Fisher Scientific, Waltham, USA) with a 60mm titanium
parallel plate geometry. Depending on their viscosity, samples were
analysed with flat, non-polished plates or serrated plates to obtain re-
liable rheological results that were not influenced by apparent wall slip
or protrusion flow (Barnes, 1995; Marchesini et al., 2015). Via a Peltier
temperature controller, the plates were kept at the standard processing
temperature used for prilling (i.e. Tmelt FA+30 °C).
The samples were measured using a gap between the plates of
2 ± 0.1mm, this ensured that the gap was at least 10 times larger than
the particle size of the suspended particles to obtain a continuous
medium (Mendes et al., 2014). The shear rate was varied from 3000 to
0.1 s−1 or 500 to 0.01 s−1 in 15 steps (log scale) for measurements
performed with flat or serrated plates, respectively. Each step was held
for 30 s to give the sample enough time to stabilize and record an ac-
curate torque value. Since sedimentation could occur during sample
loading, the shear rate was varied from higher to lower values to obtain
repeatable rheological results (Marchesini et al., 2015; Mueller et al.,
2010). All measurements were performed in triplicate, and the average
and standard deviation were calculated.
2.2.10. Solid state characterisation
The solid state of pure components, physical mixtures (180 µm) and
corresponding prills was analysed via X-ray diffraction (XRD) and
Raman spectroscopy. XRD patterns were recorded with a D5000 Cu Kα
diffractor (ʎ= 0.154 nm) (Siemens, Karlsruhe, Germany) with a vol-
tage of 40mV in the angular range of 4° < 2θ < 60° using a step scan
mode with step size of 0.02° and counting time of 1 s/step.
Raman spectra were recorded in triplicate with a Raman Rxn1
spectrometer (Kaiser Optical Systems, Ann Arbor, USA) equipped with
an air-cooled CCD detector and a 785 nm Invictus NIR diode laser over
the 0–1800 cm−1 range with a resolution of 4 cm−1, an exposure time
of 5 s and 3 accumulations. Data collection and data transfer were au-
tomated using HoloGRAMS™ data collection software (version 2.3.5,
Kaiser Optical Systems, Ann Arbor, USA). Spectra were corrected by
standard normal variate (SNV) pre-processing and centred prior to data
analysis using Simca 14.1.0 (Umetrics, Umeå, Sweden).
2.2.11. In vitro drug release
In vitro dissolution tests were performed using USP dissolution
apparatus 2 (paddle speed: 100 rpm) in combination with sinker bas-
kets to prevent floating of the hydrophobic prills. The dissolution ap-
paratus consisted of a VK 7010 dissolution system coupled to a VK 8000
automatic sampling station (Vankel, New Jersey, USA). Prills equiva-
lent with 150mg API (sink conditions) were added to 900ml dissolu-
tion medium maintained at 37 ± 0.5 °C. Four types of dissolution
media were used to evaluate the influence of pH and/or surfactants on
the drug release profile: demineralized water, phosphate buffer (pH
7.4), 0.1M HCl (pH 1) and 0.1% SLS aqueous solution. In case of dis-
solution tests on MET prills, 5 ml samples were withdrawn on 10 time
points over a 5 h, 8 h or 12 h period, depending on the drug release rate.
For dissolution tests on PAR prills, ten 5ml samples were withdrawn
during 24 h (i.e. 0.5, 1, 2, 4, 6, 8, 12, 16, 20 and 24 h). Those samples
were analysed spectrophotometrically using a double beam spectro-
photometer (UV-1650PC, Shimadzu, Antwerp, Belgium) to calculate
the API concentration from a calibration curve ranging from 1.5 to 14.7
µg/ml at a wavelength of 234 nm for MET samples and from 1.7 to 16.9
µg/ml at 243 nm for PAR samples.
Similarity between the dissolution profiles obtained in different
media was evaluated by calculating the similarity factor f2 as described
by Shah et al. (Eq. (1)), where Rt and St represent the cumulative drug
release at sample point t of the sample in the reference medium and the
sample in the alternative medium, and with n equal to the number of
total sample points. As described by Shah et al., maximum one sample
point with a cumulative drug release higher than 85% may be included
to avoid bias in the similarity assessment. Therefore, depending on the
drug release profile, 5–10 sample time points were taken into account
to calculate the similarity factor. Dissolution profiles are considered
similar if f2 is ≥50, which corresponds to an average difference of less
than 10% at all sampling time points (Shah et al., 1998).
= + =f n S R50log 1 1 ( ) 100tn t t2 10 1 2 1/2 (1)
2.2.12. Storage
Processing and storage of API/FA formulations can change the
crystalline state of formulation components and/or induce interactions
at molecular level between the different components (Becker et al.,
2015; Vervaeck et al., 2014; Del Gaudio et al., 2009; Garti and Sato,
1988). Therefore, a stability study was performed whereby immediately
after production the prills were packed in hermetically sealed bags
under controlled circumstances (< 35% RH) and stored at 25 °C and
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40 °C for 1 week, 1month, 3months and 6months. Beside evaluation of
the solid state after storage, the drug release profile was re-evaluated
throughout the stability study in demineralized water and 0.1% SLS
solution for MET and PAR prills, respectively, by evaluation of the si-
milarity factor.
2.2.13. X-ray tomography
The specific surface area and porosity of prills before and after
dissolution were evaluated using high-resolution X-ray computed to-
mography. The scans were performed at the custom-designed micro-CT
setup HECTOR of the Ghent University Centre for X-ray Tomography
(UGCT) (Masschaele et al., 2013). The tube voltage was set to 90 kV and
the power of the system was 10W. The exposure time for each project
image was 1000ms and 2401 projection images were recorded over a
360° rotation. The raw data was reconstructed using Octopus Re-
construction (TESCAN-XRE, Ghent, Belgium), using the Paganin phase
retrieval algorithm (Paganin et al., 2002). An isotropic voxel size of
4 µm was used to analyse at least 15 prills for one batch per formula-
tion.
Bespoke data processing was developed in Avizo Fire 9.5 (FEI
Visualization Sciences Group, Burlington, United States) to determine
the specific surface area of each prill from the 3D X-ray tomography
data. Initially, the tomography images were denoised using an aniso-
tropic diffusion filter in order to improve the robustness of the sub-
sequent steps. Thresholding was used to determine a binary volume
from the denoised data. A marker-based Watershed algorithm was ap-
plied on the binary volume to separate the prills and facilitate the
analysis of individual prills. The number of prills analysed is slightly
smaller (i.e. at least 10 prills per formulation) than the total number of
prills imaged as only prills visible in their entirety and clearly separated
from each other were analysed. The specific surface area was de-
termined per prill and used to normalize surface area to the prill vo-
lume. The porosity was determined from the binary volume of all prills.
3. Results and discussion
3.1. Processability
MET and PAR were selected as model APIs to evaluate the proces-
sability of API/FA suspensions since thermogravimetric analyses in-
dicated no thermal degradation of these APIs or FAs under extreme
processing conditions (i.e. 2 h at 105 °C), while hot stage microscopy
demonstrated their insolubility in molten FA under the applied pro-
cessing conditions (Fig. S1).
Prilling of API/FA suspensions initially resulted in obstruction of the
445 µm nozzle due to solidification of FA and/or (agglomeration of) the
suspended particles. Solidification of molten FA in the nozzle was
avoided by installing an extra heating pad around the nozzle of the
prilling equipment (Fig. 1g). However, nozzle obstruction still occurred
as API/FA suspensions were used instead of solutions. As the nozzle
diameter was limited (i.e. 445 µm), only a few large API particles (d90)
and/or agglomerates of the hydrophilic API in the molten hydrophobic
FA could cause nozzle obstruction. The particle size distribution of the
API in the molten FA was estimated via laser diffraction analysis where
the API was dispersed in a liquid phase with a hydrophobicity similar to
FAs (Table 2). While MET particles remained almost intact (d90
wet≈ d90 dry) when dispersed in the liquid phase, PAR agglomerates
were broken up (d90 wet≪ d90 dry). Unfortunately, nozzle obstruction
occurred and the particle size (d90) could not be sufficiently reduced by
the addition of a surfactant (0.2% polysorbate 80 or 0.2% sorbitan
monolaurate in migylol® 812), ultrasonic vibration or high shear
mixing. For example, d90 of unsieved PAR remain intact (76 ± 3 µm),
only a slight decrease to 66 µm was observed in case a high shear mixer
was used. However, sieving of the API (using a 50 and 150 µm sieve for
MET and PAR, respectively) prior to their addition to the molten FA was
efficient to reduce d90 wet (≤60 µm) of the suspended particles and
consequently prevent obstruction of the nozzle (445 µm) during pro-
cessing (Table 2), indicating the importance of size of the API particle
suspended in the FA phase.
The design of the prilling device was also essential towards the
quality of the prills. Whereas previous studies processed homogeneous
API/FA solutions, this study focused on API/FA suspensions, which are
intrinsically susceptible to sedimentation (Vervaeck et al., 2013; Nutan
et al., 2010). Hence, it was essential to identify the critical parts of the
equipment with a high probability of API sedimentation (e.g. due to
inadequate flow or stirring) and to subsequently modify the process to
ensure a constant drug content in the prills throughout the manu-
facturing process. While the flow inside the narrowed and shortened
connection tube between reservoir and nozzle (Fig. 1d) and inside the
seamless nozzle (Fig. 1j) was sufficient to avoid sedimentation of the
suspended API, it was observed that the mixing intensity inside the
reservoir remained the most critical parameter towards API sedi-
mentation. In case a smaller stirring bar was used, sedimentation oc-
curred at the seams of the melt reservoir and the drug content of the
prills increased in function of processing time. For example, prilling a
30% MET in BA formulation with a smaller stirring bar resulted in a
linearly increasing drug content from 25.5 to 28.8% during a 1 h pro-
duction process. Using of a stirring bar with a diameter equal to the
diameter of the melt reservoir avoided API sedimentation in the melt
reservoir and yielded prills with a stable drug content and a maximum
relative drug content deviation below 15% for all time points per for-
mulation, in accordance with the European Pharmacopoeia guidelines
(Table 1).
Initial screening experiments revealed that sieved (150 µm) PAR in
BA suspensions were processable up to a drug load of 20%, while sieved
(50 µm) MET in BA suspensions were processable up to a drug load of
40%. Since viscosity is a critical process parameter during droplet
formation at the nozzle, this difference in maximum processable drug
load could be attributed to the higher viscosity of PAR in BA suspen-
sions in comparison with MET in BA suspensions at equal drug loads as
illustrated in Fig. 2 (Séquier et al., 2014; Vervaeck et al., 2014; Rawle,
2010; Mastropietro et al., 2013). Rheological experiments also revealed
an almost Newtonian behaviour for MET suspensions, while distinct
shear thinning was observed for PAR suspensions.
Since the measuring temperature was kept consistently 30 °C above
the melting temperature of the selected FA, varying the FA chain length
of the formulations did not significantly change the viscosity (Fig. S2).
Consequently, the observed differences in viscosity of MET and PAR
formulations can be attributed to the varying size and shape of MET and
PAR suspended particles. Sieved MET (50 µm) and PAR (150 µm) had a
mean Feret diameter of 17 µm (span 1.84) and 13 µm (span 2.59), re-
spectively (Table 2). Due to the lower particle size of PAR in compar-
ison with MET, the number of particles and consequently the number of
particle-particle interactions at equal drug load was higher in the PAR
suspensions, resulting in a higher viscosity. Additionally, the degree of
Table 2
Particle size (d50, d90 and span) and shape (aspect ratio) of both model APIs
measured under dry and wet conditions, before and after sieving: MET – 50 µm
sieve, PAR – 150 µm sieve.
API powder: size and shape
Measuring conditions MET PAR
d50 d90 Span AR d50 d90 Span AR
(µm) (µm)
Dry Unsieved 111 277 2.26 0.73 25 505 20.69 0.71
Sieved 17 37 1.84 0.81 13 38 2.59 0.77
Wet Unsieved 118 220 1.83 NA 42 76 1.41 NA
Sieved 33 60 1.76 NA 23 52 2.23 NA
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particle-particle interactions in PAR suspensions was favoured by the
rod shape of PAR particles (AR: 0.765) in comparison with the more
spherical MET particles (AR: 0.810) as demonstrated by SEM (Fig. 3).
The elongated PAR particles were more resistant to flow as a result of
their larger specific surface area and non-suitable particle orientation.
As these particle-particle interactions are weak, their effect was more
pronounced at low shear rates what explained the shear thinning be-
haviour of the PAR formulations (Genovese, 2012; Mastropietro et al.,
2013; Mueller et al., 2010; Rawle, 2010).
Based on the initial screening experiments, the flow curve obtained
for a 20% PAR in BA suspension defined the maximum viscosity of a
formulation at a specific shear rate that allowed processing via prilling.
This observation was in accordance with the measured viscosity of
successfully processed MET (10–40%) in BA and 30% MPT in BA for-
mulations. As a remark, Del Gaudio et al. estimated the characteristic
viscosity at the nozzle via the Cross model (Robson et al., 1999; Patil
et al., 2012). In the current study, multiple processes such as stirring,
pumping and droplet formation at the nozzle were ongoing during the
prilling process and influenced the processability. Consequently, a
specific shear rate could not be defined and beyond the scope of this
article (Séquier et al., 2014). The current viscosity limit was selected
based on formulations with an observed processability.
In conclusion, the processability of API/FA suspensions was domi-
nated by the size and shape of the API powder and independent of the
FA chain length. A lower API particle size and aspect ratio resulted in
more particle-particle interactions and a higher viscosity at equal drug
load.
3.2. Size and shape of the prills
SEM imaging revealed a characteristic structure of the MET and
PAR prills, i.e. prills had an orifice at their surface that was connected
to a cavity inside the prill (Fig. 4a and b). This phenomenon was in-
dependent of drug load, which is in contrast with MPT/FA solutions
tested by Vervaeck et al. (2013). While MPT in BA prills with a low drug
load (i.e. 10% and 20%) had an orifice and cavity similar to the MET
and PAR suspension prills, at 30% MPT in BA the prills were completely
solid and spherical despite an expulsion on their surface (Fig. 4c). To
explain the observed differences in the shape of prills produced from a
suspension versus a solution, MPT in BA formulations as described by
Vervaeck et al. were further investigated in this study (Vervaeck et al.,
2015; Vervaeck et al., 2013; Vervaeck, 2015). High-speed imaging of
the droplet formation at the nozzle of a 30% MPT in BA formulation
and a 10% MET in BA formulation revealed that the droplets became
immediately spherical when released from the nozzle. The time needed
for the droplets to become spherical was< 11.6ms for the 30% MPT in
BA and<22.8ms for the 10% MET in BA (Fig. 5) formulation, re-
spectively. This spherical shape was maintained during their falling
motion before reaching the liquid nitrogen bath.
Consequently, the differences in prill shape originated from droplet
solidification in liquid nitrogen. Via high-speed imaging and RHC ex-
periments, it was demonstrated that the differences in shape can be
attributed to a difference in FA crystallization rate between API/FA
suspensions and API/FA solutions with a high drug load.
Via RHC experiments, the FA crystallization rate was evaluated for
multiple formulations. To simulate the first part of the prilling process,
physical mixtures were pretreated 30 °C above the melting temperature
of the corresponding FA, before they were rapidly cooled down
(250 °C/min) and kept isothermal just below the melting point of the
used FA. The time needed to reach the BA crystallization peak max-
imum during isothermal crystallization was short and comparable for
all API/BA suspensions, independent of API type or drug load (Fig. 6).
High-speed camera imaging indicated that the solidification of an API/
FA suspension droplet (Fig. S3) was initiated at a specific point (i.e. the
point of origin) on the surface of the droplet and continued from here in
all directions. An outer shell was quickly formed over most of the
droplet and solidification of the liquid core (i.e. crystal growth) moved
inwards from this outer layer. Due to the shrinking behaviour of FA
Fig. 2. Viscosity of API/BA suspensions and a 30% MPT in BA solution at
processing temperature (Tmelt FA+ 30 °C) in function of shear rate.
Fig. 3. SEM-images: sieved (left) MET (50 µm) and (right) PAR (150 µm) powder particles.
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during solidification, a cavity was formed inside the prill which was
connected to an orifice at the surface of the prill, in accordance to the
shrinking unsolidified core model of Séquier et al. (2014). Wu et al.
(2007), Brockmann et al. (2000). The orifice was formed at the location
where the outer shell crystallised the latest (i.e. opposite to the point of
origin). Another hypothesis to explain the formation of the cavity inside
the prills was that part of the liquid core was expelled when the surface
of the droplet shrank upon solidification. However, this hypothesis was
Fig. 4. SEM-images: surface (a, c) and cross-section (b) of prills containing (a, b) 20% MET in BA and (c) 30% MPT in BA.
Fig. 5. Spherical droplet formation at the nozzle of (a) a transparent 30% MPT in BA solution, (b) an opaque 10% MET in BA suspension in function of time.
E. De Coninck, et al. International Journal of Pharmaceutics 572 (2019) 118756
7
rejected since no core expulsion was observed via high-speed imaging.
Hence, although a cavity was formed during solidification, no mass loss
did occur.
In contrast, RHC experiments indicated that more time was needed
to reach the BA crystallization peak maximum for MPT/BA solutions
with a higher MPT load (Fig. 6). Since a 20% MPT in BA formulation
still resulted in prills with a cavity, it was assumed that once a threshold
crystallization rate was reached (i.e. between 20% and 30% MPT in BA)
droplet solidification was no longer dominated by the shrinking prop-
erties of FAs. Visualisation of droplet solidification of a 30% MPT in BA
solution via high-speed imaging showed the creation of an expulsion at
the surface of the prills (Fig. 7). When the surface of this droplet slowly
solidified from the point of origin, the unsolidified core of the droplet
due to the inner pressure created by the liquid core in a solid outer
shell. The expulsion was formed at the location where the outer shell
crystallised the latest.
When analysing the final size and shape of API/FA suspension-based
prills (Table 3), no trends in function of drug load or FA chain length
were detected. MET and PAR prills had a mean Feret diameter of
2.30mm (span 0.10) and 2.42mm (span 0.08), an average aspect ratio
of 0.905 ± 0.007 and 0.917 ± 0.012, and a sphericity of
0.937 ± 0.004 and 0.921 ± 0.007, respectively. Hence, these sphe-
rical prills had excellent flow properties.
3.3. Solid state characterisation
XRD patterns demonstrated that the crystallinity of MET, PAR and
FAs did not change by thermal processing via prilling and during sto-
rage. Characteristic peaks of MET for 2θ (e.g. 12.2° and 17.7°) and PAR
(e.g. 23.5° and 26.5°) showed up in the physical mixture and prills even
after 6months of storage while no additional peaks were observed,
confirming that MET and PAR remained in their original crystalline
form (Fig. S4). Stability of the FA crystallinity was in agreement with
the observation of Kobayashi, who stated that molten FAs exclusively
crystallized into the thermodynamically stable C-form (Kobayashi,
1988; Singleton et al., 1950). The absence of specific interactions be-
tween the components and the preservation of crystallinity during
6months storage was confirmed via Raman spectroscopy: no changes in
the characteristic Raman bands of MET, PAR and FAs were observed
(Fig. S5).
Fig. 6. Time needed to reach the BA crystallization peak maximum during isothermal crystallization in RHC as a measure for the droplet solidification rate. Both API/
BA suspensions and solutions with varying drug loads were analysed at different crystallization temperatures.
Fig. 7. Formation of an expulsion at the surface of a 30% MPT in BA prill during fast solidification in liquid nitrogen. Time after the droplet made first contact with
liquid nitrogen is indicated on the images.
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3.4. In vitro drug release
A higher drug load of a hydrophilic API can create an extensive
channel network in a hydrophobic matrix by dissolution of the API in
the dissolution medium, resulting in a faster drug release rate (Pivette
et al., 2012; Rosiaux et al., 2014). This mechanism was observed for all
MET and PAR in BA prills (Figs. 8b and 9b), except for the 10% MET in
BA prills. Despite the lower drug load in the BA prills with 10% MET
and consequently low potential to form a channel network in the ma-
trix, 63% of the drug load was released in 1 h, compared to 37%, 32%
and 49% release from BA prills containing 20%, 30% and 40% MET,
respectively. This deviating dissolution profile was attributed to an
inhomogeneous API distribution, as demonstrated via X-ray tomo-
graphy and Raman mapping. X-ray tomography showed that MET
crystals (white regions in Fig. 10a) were preferentially located at the
border of prills containing 10% MET, while at higher drug content the
drug was homogeneously distributed throughout the prill. The in-
homogeneous distribution of 10% MET in the BA matrix was confirmed
by monitoring the intensity of a characteristic MET peak (737 cm−1)
relative to a characteristic BA peak (1295 cm−1) via Raman mapping
(Fig. 10c): the relative intensity of the MET signal decreased from the
surface to the centre of a 10% MET in BA prill. These variations in
relative intensity were not observed at higher drug loads, as illustrated
for a 30% MET in BA prill in Fig. 10d. This inhomogeneous API dis-
tribution can be linked to the low viscosity of the 10% MET in BA
molten mixture (Fig. 2), allowing a higher mobility of MET particles
before solidification of the prills in comparison with MET formulations
with a higher drug load and PAR formulations. It should also be noted
that complete drug release was not obtained for 10% MET in BA prills,
as some MET crystals remained isolated in the BA matrix in comparison
with the higher MET drug loaded prills.
Similar to Vervaeck et al. (2013); Figs. 8a and 9a illustrate a faster
drug release rate when the FA chain length decreased, except for SA-
based prills. The faster release from the SA matrix was linked to the
higher porosity of these formulations independent of the API as iden-
tified via X-ray tomography (Fig. 10b and Table 4). Since the time
needed to reach the FA crystallization peak maximum during iso-
thermal crystallization of the FA was comparable (10.1 ± 0.7 s) and
fast for all 30% MET formulations (independent of the FA grade), the
origin of multiple pores in the SA-based formulations could not be
linked to its behaviour during cooling and is therefore still under re-
search.
As illustrated in Fig. 8, complete drug release of MET in deminer-
alized water depended on the drug load and FA chain length, varying
between 2.5 and 6 h. In contrast, drug release from PAR prills (Fig. 9a)
was slower: even after 24 h drug release was not complete when de-
mineralized water was used as dissolution medium. This observation
was correlated with the lower water solubility of PAR in comparison
with MET (Rosiaux et al., 2014).
mps@123456 As seen in Fig. 9b, the addition of 0.1% SLS or a
phosphate buffer to the dissolution medium enhanced the drug release of
20% PAR from BA prills. As demonstrated by Vervaeck et al., the effect of
the phosphate buffer was the result of (partial) ionization of the car-
boxylic acid group of FA, which increased the matrix hydrophilicity
Table 3
Overview of average particle size and shape of MET and PAR prills. No trends in function of drug load and/or FA chain length could be observed.
MET prills PAR prills
BA prills: influence of drug load BA prills: influence of drug load
10 20 30 40 10a 20
d50 ± SD (mm) 2.35 ± 0.02 2.31 ± 0.07 2.28 ± 0.05 2.21 ± 0.07 d50 ± SD (mm) 2.47 2.38 ± 0.06
span 0.10 0.08 0.08 0.10 span 0.07 0.09
sphericity 0.93 0.93 0.94 0.94 sphericity 0.92 0.93
aspect ratio 0.91 0.90 0.91 0.91 aspect ratio 0.93 0.93
30% MET prills: influence of FA type 20% PAR prills: influence of FA type
MA PA SA BA MA PA SA BA
d50 ± SD (mm) 2.31 ± 0.02 2.32 ± 0.01 2.33 ± 0.04 2.28 ± 0.05 d50 ± SD (mm) 2.44 ± 0.02 2.44 ± 0.02 2.40 ± 0.07 2.38 ± 0.06
span 0.12 0.10 0.10 0.08 span 0.09 0.09 0.09 0.09
sphericity 0.94 0.94 0.94 0.94 sphericity 0.92 0.92 0.91 0.93
aspect ratio 0.90 0.90 0.91 0.91 aspect ratio 0.91 0.91 0.91 0.93
a Only 1 batch could be analysed.
Fig. 8. Mean dissolution profile (± SD) of MET prills in demineralized water in
function of (a) FA chain length and (b) drug load.
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(Vervaeck et al., 2013). Since this (partial) ionization was not achieved at
pH 1 (0.1M HCl), the release profile was similar (f2=85) with the
profile obtained in demineralized water (pH 5.4). Although the SLS
concentration was below the critical micellar concentration, the surfac-
tant improved the wettability of the prills and as a result the release rate
of PAR in the dissolution medium (Pivette et al., 2012). In a phosphate
buffer or 0.1% SLS solution as dissolution medium drug release from
short chain FA prills was complete within 12 h and 16 h (Fig. 9c). No
significant effect of the dissolution medium on the release rate of MET
formulations was observed during preliminary experiments, due to the
high water solubility.
No significant differences (f2 > 50) in drug release profile were
observed after storing MET and PAR prills during 6months at 25 °C and
40 °C. This is in accordance with the solid state analysis that did not
reveal transformations.
Although all prills had a similar size with a constant drug content
per mass unit and the drug release profiles were reproducible, varia-
tions in the size of the cavity inside the prills could disturb volumetric
capsule filling with a correct API dose. Therefore, the variation in size
of the cavity within each formulation was evaluated via specific surface
area based on X-ray tomography scanning images (Table 4). For all MET
formulations, independent of drug load or FA chain length, the relative
standard deviation of the specific surface area was less than 10%. SEM
images revealed that PAR prills have a rougher microscopic surface
(Fig. 11), which was also reflected by the large specific surface area of
PAR prills compared to MET prills. Therefore, the correlation between
the specific surface area and the size of the cavity inside the prill was
disturbed.
Moreover, a high specific surface area was related to a high porosity
of the prills, as it captured the entire surface including cracks and pores.
Both specific surface area and porosity of the prills affected the drug
release rate, where a low specific surface area/porosity slowed down
the dissolution process. The slowest drug release was observed for the
BA formulations (Figs. 8a and 9a for MET and PAR formulations, re-
spectively) with the smallest porosity per formulation.
As a conclusion, the presence of a cavity inside the prill is not
problematic since the drug release profiles were reproducible and high-
speed imaging analysis in combination with RHC measurements de-
monstrated that the cavity was formed due to shrinking during cooling
without mass loss.
4. Conclusion
This study indicated that prilling of API/FA suspensions is a pro-
mising technique for the production of lipid-based multi-particulate
Table 4
Average specific surface area, its relative standard deviation and the porosity of
at least 10 MET prills per formulation based on X-ray tomography image ana-
lysis.
X-ray tomography data processing
Formulation Specific surface areaa Porosity
Average (mm−1) Relative standard deviation (%) (%)
10% MET in BA 3.30 8.85 0.17
20% MET in BA 3.25 4.25 0.11
30% MET in MA 3.40 2.72 0.24
30% MET in PA 3.27 4.53 0.06
30% MET in SA 3.89 3.54 0.48
30% MET in BA 3.06 3.60 0.04
40% MET in BA 3.94 6.13 0.43
10% PAR in BA 4.34 14.54 0.75
20% PAR in MA 5.17 9.1 1.23
20% PAR in PA 3.89 7.42 0.36
20% PAR in SA 7.78 10.57 2.41
20% PAR in BA 4.07 5.92 0.24
a Normalized surface area to prill volume.
Fig. 9. Mean dissolution profile (± SD) of PAR prills in function of (a) FA chain
length in demineralized water, (b) drug load and (b, c) dissolution medium.
E. De Coninck, et al. International Journal of Pharmaceutics 572 (2019) 118756
10
spherical dosage forms. The processability of API/FA suspensions was
only limited by the viscosity of the molten mixture, which was mainly
affected by the size and shape of the API particles, but was independent
of the FA chain length. API/FA suspensions showed a fast re-
crystallization of their FA fraction upon cooling, resulting in prills with
an orifice at their surface that was connected to a cavity inside the prill,
without negatively influencing the reproducibility of the drug release.
The collected API/FA suspension-based prills were spherical with a
smooth surface and had a particle size independent of the drug load
and/or FA chain length. In vitro drug release evaluation revealed a
faster drug release at higher drug load, higher API water solubility and
shorter FA chain length. In future experiments upscaling of the prilling
process will be studied to increase the production capacity. A system
where droplets will be formed by the laminar jet break-up of a con-
tinuous flow via a vibrating nozzle will be evaluated. Subsequently, the
droplets will be solidified during their falling motion in a cooling tower.
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